Open Access

CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker

  • Authors:
    • Hao Hu
    • Yuan Xiang
    • Xiao-Yu Zhang
    • Yang Deng
    • Fu-Jian Wan
    • You Huang
    • Xing-Hua Liao
    • Tong-Cun Zhang
  • View Affiliations

  • Published online on: August 16, 2022     https://doi.org/10.3892/or.2022.8387
  • Article Number: 172
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cell division cycle‑associated 5 (CDCA5) plays a critical role in the progression of various human cancers by regulating cell cycle‑related proteins; however, the function of CDCA5 in breast cancer (BC) is poorly understood. The aim of the present study was to investigate the expression level of CDCA5 in BC and its effect on BC progression. CDCA5 was found to be highly expressed in patients with BC, as well as in BC cell lines. It was also found that a high CDCA5 expression in BC was significantly associated with a shorter survival rate. In addition, the expression level of CDCA5 was significantly increased in stem cells derived from suspension‑cultured BC cells, as compared to adherent‑cultured cells. CDCA5 knockdown in MCF7 and SKBR3 cells significantly reduced cell proliferation, migration and clone formation. At the same time, the stemness capacity of BC cells, determined by analyzing cancer stem cell marker expression and mammosphere formation, was also markedly diminished following the knockdown of CDCA5. In addition, in vivo experiments demonstrated that CDCA5 knockdown in MCF7 cells markedly reduced tumor growth. On the whole, the present study demonstrates that CDCA5 may be used as a prognostic biomarker and therapeutic target for BC.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 48 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu H, Xiang Y, Zhang X, Deng Y, Wan F, Huang Y, Liao X and Zhang T: CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker. Oncol Rep 48: 172, 2022
APA
Hu, H., Xiang, Y., Zhang, X., Deng, Y., Wan, F., Huang, Y. ... Zhang, T. (2022). CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker. Oncology Reports, 48, 172. https://doi.org/10.3892/or.2022.8387
MLA
Hu, H., Xiang, Y., Zhang, X., Deng, Y., Wan, F., Huang, Y., Liao, X., Zhang, T."CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker". Oncology Reports 48.4 (2022): 172.
Chicago
Hu, H., Xiang, Y., Zhang, X., Deng, Y., Wan, F., Huang, Y., Liao, X., Zhang, T."CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker". Oncology Reports 48, no. 4 (2022): 172. https://doi.org/10.3892/or.2022.8387